ALEXANDRIA, Va., March 19 -- United States Patent no. 12,252,701, issued on March 18, was assigned to KITE PHARMA INC. (Santa Monica, Calif.).
"Chimeric antigen receptor T cell therapy" was invented by Adrian Bot (Beverly Hills, Calif.) and Michael David Mattie (Torrance, Calif.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to an...